ADA and rheumatoid arthritis: In conclusion, these results indicated that in this relatively large, multinational, cross-sectional real-world population of patients with RA receiving treatment for 6 to 24 months, ADA developed in a higher proportion of patients receiving an anti-TNF monoclonal antibody (ADL or IFX) than in patients receiving a soluble dimeric TNF receptor fusion protein (ETN).